IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.

Trial Details

NCT ID

NCT07122687

Phase

PHASE2

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Pemetrexed
Cisplatin
IBI363
Carboplatin
Keytruda

Locations (sample)

Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

Males and Females, age ≥18 years and ≤75 years;
Histologically or cytologically confirmed primary non-squamous NSCLC:
Stage IB, II, IIIA or IIIB (N2) NSCLC (per AJCC8);
No administration of any anti-NSCLC therapy in the pre-operative period;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →